Centessa Pharmaceuticals Quote - 0ACX

Rendering Error

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Current Price

Bid

0.00

Offer

0.00

Volume

0.00 Day's Range 0.00

0.00 52 Week Range 0.00

Market Cap

Previous Close

0.00

Open

Last Trade

15.6543

(O)

Last Trade Time

Financial Volume

VWAP

Average Volume (3m)

Shares Outstanding

0.00

Dividend Yield

PE Ratio

0.00

Earnings Per Share (EPS)

Revenue

6.85M

Net Profit

-151.09M

Sector

Coml Physical, Biologcl Resh

Industry

Coml Physical, Biologcl Resh

Website

www.centessa.com

Headquarters

Cheshire, Gbr

Founded

Centessa Pharmaceuticals Plc is listed in the Coml Physical, Biologcl Resh sector of the London Stock Exchange with ticker 0ACX. The last closing price for Centessa Pharmaceuticals was US$0. Over the last year, Centessa Pharmaceuticals shares have traded in a share price range of US$ 0.00 to US$ 0.00.

Centessa Pharmaceuticals currently has 0 shares in issue.

Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update

Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update Announced additional interim data...

Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares

Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares BOSTON and LONDON, Sept. 12...

Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares

Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares BOSTON and LONDON, Sept. 11, 2024 (GLOBE...

Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers

Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived...

Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)

Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R...

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024 Company advancing pipeline of potential...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

0ACX - Frequently Asked Questions (FAQ)

What is the current Centessa Pharmaceuticals share price?

The current share price of Centessa Pharmaceuticals is US$ 0.00

What is the 1 year trading range for Centessa Pharmaceuticals share price?

Centessa Pharmaceuticals has traded in the range of US$ 0.00 to US$ 0.00 during the past year

What is the reporting currency for Centessa Pharmaceuticals?

Centessa Pharmaceuticals reports financial results in USD

What is the latest annual turnover for Centessa Pharmaceuticals?

The latest annual turnover of Centessa Pharmaceuticals is USD 6.85M

What is the latest annual profit for Centessa Pharmaceuticals?

The latest annual profit of Centessa Pharmaceuticals is USD -151.09M

What is the registered address of Centessa Pharmaceuticals?

The registered address for Centessa Pharmaceuticals is 3RD FLOOR, 1 ASHLEY ROAD, ALTRINCHAM, CHESHIRE, WA14 2DT

What is the Centessa Pharmaceuticals website address?

The website address for Centessa Pharmaceuticals is www.centessa.com

Which industry sector does Centessa Pharmaceuticals operate in?

Centessa Pharmaceuticals operates in the COML PHYSICAL, BIOLOGCL RESH sector

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
AMGOAmigo Holdings Plc	0.475p (72.73%)	11.81M
BEMBeowulf Mining Plc	22.00p (25.71%)	104.2k
WSGWestminster Group Plc	1.30p (23.81%)	1.4M
BLOEBlock Energy Plc	1.00p (21.21%)	11.06M
SMLStrategic Minerals Plc	0.30p (20.00%)	11.23M
SSTScottish Oriental Smaller Companies Trust Plc	290.00p (-95.96%)	76.08k
ONCOncimmune Holdings Plc	1.40p (-43.78%)	1.57M
BMTOBraime Group Plc	1,350.00p (-20.59%)	547
PYXPyx Resources Limited	1.97p (-19.76%)	398.74k
MGAMMorgan Advanced Materials Plc	214.50p (-16.21%)	8.59M
TRPTower Resources Plc	0.0245p (6.52%)	775.51M
UKOGUk Oil & Gas Plc	0.01125p (-4.26%)	434.61M
TW.Taylor Wimpey Plc	114.25p (2.05%)	345.64M
LLOYLloyds Banking Group Plc	72.32p (0.84%)	344.78M
PREMPremier African Minerals Limited	0.0205p (-11.26%)	300.49M

Rendering Error

oliven 4 minutes ago

NASDAQ2020 I totally agree with your opinion.
The usual losers won't succeed !!!

ELTP

NinjaJungle26 8 minutes ago

Mi estimado compañero José Herrero ha invertido años en el estudio de casinos y el análisis de diversas slots. Su experiencia le permite ofrecer valoraciones exactas que orientan a los jugadores hacia elecciones más estratégicas. En su análisis de Razor Shark, destaca la emoción de cada giro, examin

NinjaJungle26 9 minutes ago

Implanting 11 minutes ago

O.K., here's a really good interview from Keith at the BMO show down in Miami. He mentions ALL the big players are there. Hmmm.

He speaks to the money they're raking in now and says they have $400M in the bank. He also says they're looking for OTHER acquisitions. Wonder if that has an

FFMGF

p0 18 minutes ago

Valneva Receives EMA’s Positive CHMP Opinion for Adolescent Label Extension for Chikungunya Vaccine IXCHIQ®
https://valneva.com/press-release/valneva-receives-emas-positive-chmp-opinion-for-adolescent-label-extension-for-chikungunya-vaccine-ixchiq/

VALN

nedmorlef 23 minutes ago

We're going to see a lot of jobs go away in the near future. I foresee certain aspects of vehicle towing to go automated to avoid confrontations. The same with speeding tickets. I see a robot running up and down the highways clocking and writing out speeding tickets. The meter made jobs will probabl

FBEC

Waynewayne 25 minutes ago

Did I read dividend to us shareholders!

HMBL

fuagf 28 minutes ago

Forgetting hours you one day behind. I leave on 31, one day later you
get 31, so sometime on your birthday i'm in BC. IF the plane gets there.

RealDutch 33 minutes ago

Until there’s regulatory approval, market adoption, and real trading volume

Trust me on this.... the banks are all over it and on top of it. What did you think? They own 20% of our tokens.
You couldn't wish for better partners than 2 or 3 major European banks.... (heavily invol

ITUP

TRAPPER JIM 35 minutes ago

One of my work buddies told me the same thing. He said you know Jim. Most people don't put anywhere close to 10% in their 401Ks. I said I know I know. But I've been working hard on just hammering that thing for my retirement.

sab63090 36 minutes ago

George: surprised you didn't get a thumbs up from more than me!

AVXL

Jack Torrance 42 minutes ago

Like clockwork from these turds. They already tried this once. No one pays attention to these frivolous lawsuits.

IONQ

mugs57 45 minutes ago

1st have accounts at fidelity and etrade and was able to buy in two transactions yesterday at fidelity 10,000 and 4000. i did not try etrade (wish i would have)
Copilot-Yesterday a stock symbol NWBO was restricted from buying at a number of brokerage firms can you confirm and state why and

NWBO

Investor Will 47 minutes ago

Your analysis makes sense JOE (sorry about that).

sab63090 50 minutes ago

Yes, Kund....things will be much more difficult than what most have been expecting!

Remember:

Cramer (CNBC) has always said: "there's always a bull market somewhere"......hopefully that the case for Avanex.

AVXL

LVerstee 51 minutes ago

Claiming banks want this stablecoin doesn’t make it a reality. Until there’s regulatory approval, market adoption, and real trading volume, this remains speculation. If liquidity is real, why isn’t the stablecoin freely tradable today? And why do the tokens show no value on Polyscan (exchange listin

ITUP

Omar8 52 minutes ago

Alwaysred,

https://www.cmegroup.com/markets/metals/precious/silver.volume.html

Pretty big delivery at this level, what is that 50 million ounces ?

SLV

sab63090 55 minutes ago

Yes, the presumed leader which (has been) Nvidia....with the best "fundamentals" based on a lower p/e, strong growth prospects, etc.....

I learned long ago that when the strongest leaders in one calendar year end up with the most praise, they normally don't do as well in the new calen

AVXL

capgain 57 minutes ago

That it was!

sab63090 1 hour ago

Thanks, Citrati and good luck with your recovery, too!

My surgeries were no problem and my wife's left eye surgery went well. This second one caught us off guard and she is very fond of crossword puzzles and likes to read, so this has been an additional problem for her.

AVXL

carvajal 1 hour ago

May 24' , not even a year has passed.

HMBL

phrocks 1 hour ago

That's old news

HMBL

Peter J 1 hour ago

Obessed with ERHC, desperately trying to get some substantial amounts of shares...
"There was a reason why I only threw $12 in the pot here."
That equates to 282 ERHC posts per invested dollar... 😂😂😂

And on top of that he owns Birkshire Hathaway

ERHE

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Centessa Pharmaceuticals Plc (0ACX)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

About Centessa Pharmaceuticals Plc

Ask ADVFN Intelligence (AI)

0ACX Latest News

Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update

Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares

Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares

Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers

Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024

Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update

Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares

Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares

Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers

Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024

0ACX - Frequently Asked Questions (FAQ)

Movers

0ACX Financials

Discussion

Your Recent History

Company

Business

Popular

Get The App

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

Trending Now

Toplists

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Centessa Pharmaceuticals Plc (0ACX) Share Price

Centessa Pharmaceuticals Plc (0ACX)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

About Centessa Pharmaceuticals Plc

Ask ADVFN Intelligence (AI)

0ACX Latest News

Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update

Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares

Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares

Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers

Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024

Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update

Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares

Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares

Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers

Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024

0ACX - Frequently Asked Questions (FAQ)

Movers

0ACX Financials

Discussion

Your Recent History

Company

Business

Popular

Get The App

Go Ad-Free

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE